Abstract

Determination of human papillomavirus (HPV) status has become clinically relevant for head and neck squamous cell carcinoma (HNSCC) patients. p16 immunohistochemistry is one of the recommended methods for classifying HPV status. However, long noncoding RNAs (lncRNAs) and related competing endogenous RNA (ceRNA) networks linked to different p16-status HNSCC are still absent.

In the present study, The Cancer Genome Atlas database provided RNA profiles as well as clinical information from 26 p16-positive HNSCC samples, 71 p16-negative HNSCC samples, and 44 adjacent normal control samples. Differentially expressed RNAs (DERNAs) between HNSCC samples and normal samples were identified by limma package in R. Functional enrichment analysis of differentially expressed mRNAs was performed using ClusterProfiler package in R. Survival analysis of DERNAs was carried out by survival package in R. The ceRNA network was constructed using GDCRNATools package in R.

A total of 102 IncRNAs, 196 microRNAs (miRNAs), and 2282 mRNAs were identified as p16-positive-specific DERNAs. There were 90 IncRNAs, 153 miRNAs, and 2038 mRNAs were identified as p16-negative-specific DERNAs. Functional enrichment analysis revealed that the differentially expressed mRNAs in the p16-positive and the p16-negative group were mainly enriched in the “DNA replication” and “extracellular matrix-receptor interaction” pathway, respectively. Among the top 25 DERNAs, there were 1 key IncRNA, 1 key mRNA, and 1 key messenger RNA in the p16-positive group and 2 key IncRNAs, 1 key miRNA, and 2 key mRNAs in the p16-negative group were significantly related to the overall survival. Then the ceRNA network in the p16-positive and p16-negative group was constructed. There were 5 IncRNAs, 16 miRNAs, and 66 mRNAs included in the p16-positive group ceRNA network and 1 IncRNA, 4 miRNAs, and 28 mRNAs included in the p16-negative group ceRNA network. Among the RNAs in the ceRNA network, 5 mRNAs were significantly related to the overall survival.

Taken together, we revealed the differential RNA expression profiling and the differential ceRNA network in the p16-positive and p16-negative group of HNSCC. Our findings provided a novel insight into this HPV-related cancer and potential biomarkers and therapeutic targets for HNSCC based on p16 status.

Abbreviations: AJCC = American Joint Commission on Cancer, BP = biological process, CC = cellular component, ceRNA = competing endogenous RNA, DElncRNA = differentially expressed lncRNA, DEMiRNA = differentially expressed miRNA, DERNA = differentially expressed mRNA, DERNAs = differentially expressed RNAs, FC = fold change, FDR = false discovery rate, GO = Gene Ontology, HNSCC = head and neck squamous cell carcinoma, HPV = human papillomavirus, IHC = immunohistochemistry, KEGG = Kyoto Encyclopedia of Genes and Genomes, IncRNAs = long noncoding RNAs, MF = molecular function, miRNA = microRNA, mRNA = messenger RNA, ncRNAs = noncoding RNAs, OPSCC = oropharyngeal squamous cell carcinoma, OS = overall survival, TCGA = The Cancer Genome Atlas, UICC = Union for International Cancer Control.

Keywords: competing endogenous RNA, head and neck squamous cell carcinoma, long noncoding RNA, p16, prognosis
1. Introduction

Head and neck squamous cell carcinoma (HNSCC) ranks as the sixth most common cancer worldwide. It has a yearly incidence of 660,000 cases with 40%–50% mortality. The carcinogenesis relates to different etiologies and a large variety of molecular changes. Tobacco use and excessive alcohol consumption are the major classical risk factors for HNSCC. Currently, human papillomaviruses (HPVs) have emerged as a novel risk factor for HNSCC, especially for oropharyngeal squamous cell carcinoma (OPSCC). In general, patients with HPV-positive OPSCC tend to be a relatively younger age than their HPV-negative counterparts and less likely to be smokers or excessive alcohol consumers. Moreover, they tend to be more frequently male and have a better overall prognosis. Although the effect of HPV in HNSCCs located outside the oropharynx is less well understood, HPV positivity is also associated with more favorable outcomes. p16 is a tumor suppressor protein that is over-expressed in HPV-driven carcinomas. Many research showed that p16 immunohistochemistry (IHC) is a cost-effective method with good sensitivity and negative predictive value. This method is recommended as a surrogate marker of HPV status by the Union for International Cancer Control and the College of American Pathologists. However, the precise mechanisms of how p16-positive HNSCC and p-16 negative HNSCC occurs and progresses are still not elucidated.

Tumorigenesis and cancer development has been closely associated with the aberrant expression of RNAs. Less than 2% of the total genome encodes protein-coding genes, suggesting that noncoding RNAs (ncRNAs) represent most of the human transcriptome. Long noncoding RNAs (lncRNAs) are defined as transcripts of more than 200 nucleotides and have been implicated in a diverse range of biological processes (BPs) in cancer. MicroRNAs (miRNAs) are short ncRNAs, with a length of approximately 18–25 nucleotides. They are evolutionarily conserved and are pivotal post-transcriptional mediators of gene regulation. In 2011, Salmena et al. hypothesized a novel regulatory mechanism between lncRNAs and messenger RNAs (mRNA), namely competing endogenous RNA (ceRNA) network. In this theory, ceRNAs regulate each other by competing specifically for shared miRNAs. miRNA competition thus extends beyond the noncoding transcriptome to protein-coding mRNAs. Increasing evidence has confirmed that the lncRNA-miRNA-mRNA ceRNA network plays key roles in human cancers, such as esophageal cancer, lung cancer, as well as HNSCC. However, current knowledge for lncRNA-miRNA-mRNA in human cancers is not enough, including p16-positive and p16-negative HNSCC.

In the current study, to detect the aberrant expression profile of ncRNAs and mRNAs in p16-positive and negative HNSCC patients, the p16-positive and negative HNSCC tissue and normal tissue expression profiles from The Cancer Genome Atlas (TCGA) database were obtained. Subsequently, a functional enrichment analysis for these aberrantly expressed mRNAs was conducted. Furthermore, p16-positive group and p16-negative group ceRNA networks were constructed including differentially expressed RNAs (DERNAs). Kaplan-Meier analysis was performed to identify key DERNAs and ceRNA-related RNAs that are associated with overall survival (OS). They may also serve as promising diagnostic biomarkers and therapeutic targets for different p16 status HNSCC in the future.

2. Materials and Methods

2.1. Data collection and processing

Gene expression data (RNA sequencing profiles and miRNA profiling) and corresponding clinical data of HNSCC were downloaded from the TCGA database (https://portal.gdc.cancer.gov/). The inclusion criteria were set as follows: the p16 IHC status of HNSCC samples were recorded and patients with complete data including age, gender, OS time, and vital status. The exclusion criteria were set as follows: the p16 IHC status of HNSCC samples were unrecorded and patients with incomplete clinicopathological data. According to the criteria, 97 primary HNSCC samples, including 26 patients with immunohistochemically p16-positive status (p16-positive group) HNSCC and 71 patients with immunohistochemically p16-negative status (p16-negative group), and 44 normal controls were collected in our analysis. The clinicopathological characters of the p16-positive and p16-negative group HNSCC patients are shown in Table 1.

Among these data, mRNA and lncRNA data were collected from Illumina HiSeqRNASeq platforms, and miRNA data were collected from Illumina HiSeqmiRNASeq platforms. mRNAs and lncRNAs were encoded according to the ENSEMBL database version 89, European Bioinformatics Institute, Cambridge, UK (https://www.ensembl.org), miRNAs were annotated according to miRbase version 22, The University of Manchester, Manchester, UK (http://www.mirbase.org). The ethical approval of American Pathologists.

### Table 1

Clinicopathological characters of the p16 positive and p16 negative HNSCC patients.

| Characteristics | p16 positive HNSCC patients | p16 negative HNSCC patients |
|-----------------|-----------------------------|-----------------------------|
| Age             |                             |                             |
| <60             | 18 (69.2)                   | 35 (49.3)                   |
| ≥60             | 8 (30.8)                    | 36 (50.7)                   |
| Gender          |                             |                             |
| Male            | 23 (88.5)                   | 54 (76.1)                   |
| Female          | 3 (11.5)                    | 17 (23.9)                   |
| Pathologic stage|                             |                             |
| Stage I         | 1 (3.85)                    | 5 (7.0)                     |
| Stage II        | 3 (11.5)                    | 5 (7.0)                     |
| Stage III       | 1 (3.85)                    | 9 (12.7)                    |
| Stage IV        | 10 (35.6)                   | 44 (62.0)                   |
| NA              | 11 (42.3)                   | 8 (11.3)                    |
| Pathologic T    |                             |                             |
| T1–T2           | 10 (38.5)                   | 20 (28.2)                   |
| T3–T4           | 7 (26.9)                    | 43 (60.5)                   |
| Tx              | 9 (34.6)                    | 8 (11.3)                    |
| Pathologic N    |                             |                             |
| N0              | 3 (11.5)                    | 16 (22.5)                   |
| N1–N3           | 12 (46.2)                   | 48 (67.6)                   |
| Nx              | 11 (42.3)                   | 7 (9.9)                     |
| Vital status    |                             |                             |
| Alive           | 22 (84.8)                   | 46 (64.8)                   |
| Dead            | 4 (15.4)                    | 25 (35.2)                   |

HNSCC = head and neck squamous cell carcinoma, NA, N, Tx = pathologic stage is unknown.
was not necessary. This study conformed with the publication guidelines provided by TCGA and all the data are publicly available.

2.2. Analysis of differentially expressed IncRNAs, mRNAs, and miRNAs

The differentially expressed lncRNA (DElncRNA), mRNA (DEmRNA), and miRNA (DEmiRNA) in p16-positive HNSCC samples and normal controlled samples or p16-negative HNSCC samples and normal controlled samples were identified using “limma” package of R software. $P$ value was adjusted to the false discovery rate (FDR). $\log_2$ Fold Change$>1.0$ and FDR $<0.01$ were used as statistically significant. In order to visualize the results of differential genetic analysis, the heatmaps were plotted using “heatmap” packages of R software.

2.3. Functional enrichment analysis

To understand the potential mechanisms involved in the tumorigenesis of p16-positive and p16-negative HNSCC, Gene Ontology (GO) functional enrichment, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed on DEmRNAs using “ClusterProfiler” package of R software. A $P < .01$ was considered as enriched gene sets.

2.4. Survival analysis

To investigate the prognostic characteristics of DERNAs in different p16 status groups, the p16-positive group and p16-negative group HNSCC samples were divided into the high expression group or the low expression group (according to the median) in terms of the expression of lncRNAs, mRNAs, and miRNAs, separately. To correlate the DERNAs with the OS, the survival curves were plotted using “survival” package of R software based on the Kaplan-Meier method. A $P < .05$ was considered statistically significant.

2.5. Construction of IncRNA-miRNA-mRNA ceRNA network

Based on the theory that lncRNAs can invoke miRNA sponges to affect the expression of mRNA, we predict the interactions between DElncRNA and DEmiRNA and DEmRNA. A ceRNA network was constructed by using “GDCRNATools” package of R software.[17] The ceRNA network was visualized using Cytoscape 3.6.1 software, Institute for Systems Biology, Seattle, USA.

3. Results

3.1. Screening of differentially expressed RNAs in the p16-positive group and p16-negative group HNSCC samples

By comparing the expression of RNAs between the p16-positive (or negative) group HNSCC tissue samples with normal tissue samples, we identified some DERNAs. According to the cutoff criteria of $\log_2$ Fold Change$>1.0$ and an FDR $<0.01$, 102 DElncRNAs (56 upregulated and 46 downregulated), 196 DEmiRNAs (89 upregulated and 107 downregulated), and 2282 DEmRNAs (970 upregulated and 1312 downregulated) were identified in the p16-positive group. In the p16-negative group, 90 DElncRNAs (45 upregulated and 45 downregulated), 153 DEmiRNAs (72 upregulated and 81 downregulated), and 2038 DEmRNAs (1012 upregulated and 1026 downregulated) were identified. The variable expression of differentially expressed DElncRNAs, DEmiRNAs, and DEmRNAs between the p16-positive (Fig. 1A) group (or the p16-negative group [Fig. 1B]), HNSCC samples with the normal controls were visualized in the heatmap. The top 25 differentially expressed DElncRNAs/DEmiRNAs/DEmRNAs in the p16-positive group and the p16-negative group HNSCC samples compared with normal controls were listed. See Table S1, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DElncRNAs in the p16-positive group. See Table S2, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DEmiRNAs in the p16-negative group. See Table S3, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DEmRNAs in the p16-positive group. See Table S4, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DEmRNAs in the p16-negative group. See Table S5, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DEmRNAs in the p16-negative group. See Table S6, Supplemental Digital Content, http://links.lww.com/MD/H39, which illustrates the top 25 differentially expressed DEmRNAs in the p16-negative group.

3.2. Functional enrichment analysis for DEmRNAs in the p16-positive group and p16-negative group

To further analyze the biological function and corresponding pathways of DEmiRNAs in the p16-positive group and the p16-negative group, GO and KEGG analysis was performed. GO annotation consists of cellular component, BP, and molecular function. The top 5 enrichment scores in GO analysis of the p16-positive group and the p16-negative group were shown in Figure 2A and B. Additionally, the top 10 KEGG pathways of the p16-positive and the p16-negative group were shown in Figure 2A and B. The DNA replication pathway was found to have the lowest $P$ value in the p16-positive group and the pathview was shown in Figure 2C. The extracellular matrix(ECM)-receptor interaction pathway was found to have the lowest $P$ value in the p16-negative group and the pathview was shown in Figure 2D.

3.3. Prognostic OS assessment of key DElncRNAs, DEmiRNAs, and DEmRNAs in the p16-positive and p16-negative group

To evaluate the prognostic signatures of DElncRNAs, DEmiRNAs, and DEmRNAs, the survival analysis was performed and a $P < .05$ was considered as a cutoff. In the p16-positive group, a total of 9 DElncRNAs, 31 DEmiRNAs, and 167 DEmRNAs were significantly related to the OS. In the p16-negative group, a total of 10 DElncRNAs, 9 DEmiRNAs, and 106 DEmRNAs were significantly related to the OS. Combined with the results of survival analysis and expression analysis, we redefined the key DElncRNAs/DEmiRNAs/DEmRNAs as the top 25 upregulated or downregulated DElncRNAs/DEmiRNAs/DEmRNAs, which could also indicate the OS of HNSCC patients significantly. In the p16-positive group, key DElncRNA (U62317.3), key DEmiRNA (hsa-miR-375), and key DEmRNA (KLHDC7B) were found (Fig. 4A). Similarly, there were 2 key DElncRNAs (AL161431.1, ZNF667-AS1), 1 key DEmiRNA (has-miR-424-5p), and 2 key DEmRNAs (FAM3B, PTHLH) (Fig. 4B) in the p16-negative group.

3.4. Construction and analysis of IncRNA-miRNA-mRNA ceRNA network in the p16-positive group and p16-negative group

To further understand the interaction between DElncRNAs, DEmiRNAs, and DEmRNAs in the p16-positive group and the p16-negative group, the ceRNA networks were constructed. In the p16-positive group, 5 IncRNA nodes, 16 miRNA nodes,
66 mRNA nodes, and 162 edges were identified. In the p16-negative group, 1 lncRNA node, 4 miRNA nodes, 28 mRNA nodes, and 59 edges were identified. Cytoscape was used to visualize the p16-positive group (Fig. 5A) and the p16-negative group (Fig. 5B) ceRNA network.

3.5. Identify the RNAs in the p16-positive and p16-negative group ceRNA network associated with HNSCC patient OS

To identify critical RNAs that play important roles in both the BP and prognosis of the ceRNA network, Kaplan-Meier estimate and log-rank test were used to determine the relationship between OS and RNAs in the ceRNA network. In the p16-positive group, 3 mRNAs (PDLIM5, USP25, SLMAP) were observed to be significantly related to OS ($P < .05$) (Fig. 6A). In the p16-negative group, 2 mRNAs (ITGA5, ADA) were observed to be significantly related to OS ($P < .05$) (Fig. 6B).

4. Discussion

HNSCCs affect more than 660,000 patients per year worldwide. Despite surgery, radiation, and chemotherapy, approximately half of patients will die of the disease. Smoking is implicated in the rise of HNSCC in developing countries, and
the infection of HPV is emerging as an important factor in the rise of HNSCCs affecting nonsmokers in developed countries. [19] HPV-positive HNSCC has unique epidemiological and clinicopathological features. [20] In HPV-driven tumorigenesis, the HPV E6 and E7 oncoproteins decrease the level of p53 and pRb by post-translational regulation, leading to aberrant...

Figure 2. The top 5 enrichment scores in GO enrichment analysis of DEmRNAs. (A) CC, BP, MF of DEmRNAs in the p16-positive group; (B) CC, BP, MF of DEmRNAs in the p16-negative group. ATPase = adenosine-triphosphate synthase, BP = biological process, CC = cellular component, DEmRNAs = differentially expressed mRNAs, GO = Gene Ontology, MF = molecular function.

Figure 3. The top 10 enrichment scores in KEGG pathway analysis of the DEmRNAs in the p16-positive group. (A) and in the p16-negative group (B). (C) DNA replication map from KEGG analysis; (D) ECM-receptor interaction map from KEGG analysis, the red colors represent the upregulated DEmRNAs green colors represent the downregulated DEmRNAs, DMP1 = dentin matrix acidic phosphoprotein 1, Dna2 = DNA replication helicase/nuclease 2, DPP = dipeptidyl peptidase, DSP = desmplakin, ECM = extracellular matrix, FEN1 = flap structure-specific endonuclease 1, FRAS1 = Fraser extracellular matrix complex subunit 1, FREM1/2 = FREM1 related extracellular matrix ½, GPib \alpha = glycoprotein Ib platelet subunit alpha, GPib \beta = glycoprotein Ib platelet subunit beta, GPIX = glycoprotein IX platelet, GPV = glycoprotein V platelet, HA = glucose-6-phosphate isomerise, Ig-SF = junctophilin 4, Lig I = tumor protein P53, KEGG = Kyoto Encyclopedia of Genes and Genomes, MCM = minichromosome maintenance, Npnt = nephronecin, OPN = ostitrotic receptor, PPAR = peroxisome proliferator activated receptor alpha, PSK-Akt = phospholipidinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha-AKT serine/threonine kinase, PPAR = peroxisome proliferator activated receptor, RFC = ribonucleic acid carrier family 19 member 2, RHAMM = hyaluronan mediated motility receptor, RNase = ribonuclease, RPA, RPA interacting protein, SV2 = SV2 related protein, THBS = thrombospondin 1, VLA = integrin subunit alpha 4, VWF = von willebrand factor, \alpha DG = dystroglycan 1, \alpha-Prim = DNA polymerase alpha 1, catalytic subunit, \beta DG = dolichyl-phosphate mannosyltransferase subunit 3, regulatory.
overexpression of the cell-cycle protein p16 (CDKN2A).\cite{21-24} HPV infection can be detected by various mechanisms. p16 IHC is a commonly used and well-established surrogate marker for detection HPV in HNSCC and has become the recommended standalone prognostic test for OPSCC patients. As underlined in the 8th edition American Joint Commission on Cancer staging guidelines, p16 IHC is required to stage OPSCC patients.\cite{25} Some studies demonstrated that p16 IHC positivity is also an independent and positive prognostic factor in non-OPSCC.\cite{26,27} Although some other studies are contradictory to the results,\cite{28} the HPV status classifies 2 distinct entities of HNSCC and p16-positive and p16-negative HNSCC have significantly different disease profiles. We hope that the study of the molecular difference between p16-positive and p16-negative HNSCC will help with the exploration of HNSCC heterogeneity. However, integrated and comprehensive analysis of lncRNA, miRNA, mRNA, and associated ceRNA network in non-OPSCC.\cite{26,27}

In this present study, using the TCGA database, we identified a total of 102 DElncRNAs, 196 DEmiRNAs, and 2282 mRNAs as p16-positive-specific DERNA. We also identified 90 DElncRNAs, 153 DEmiRNAs, and 2038 DEmRNAs as p16-negative-specific DERNA based on the differential expression between tumor tissues and adjacent normal tissues. GO analysis is widely used as a functional enrichment analysis for a large number of genes.\cite{29} The results of GO analysis demonstrated that the p16-positive-specific and p16-negative-specific DEmRNAs were significantly enriched in some different GO terms that were associated with cancer biological behaviors. In the p16-positive group, the DEmRNAs were significantly enriched in the condensed chromosome, DNA replication, and single-strand DNA-dependent ATPase activity. In the p16-negative group, the DEmRNAs were significantly enriched in the extracellular matrix, extracellular matrix organization, and extracellular matrix structural constituent. KEGG pathway enrichment analysis revealed that multiple different enriched pathways were obtained according to the p16-status. In the p16-positive group, the pathways involving in cancer mainly include DNA replication, cell cycle, and p53 signaling pathway. In the p16-negative group, the upregulated pathways related to cancer mainly enriched in ECM-receptor interaction, focal adhesion, and PI3k-Akt signaling pathway. Thus, these significant DEmRNAs may be involved in different modulation of HNSCC carcinogenesis and progression based on disparate p16-status.

For further identifying key DERNA in p16-positive and p16-negative HNSCC, the top 25 upregulated and downregulated DERNA were selected for further expression and survival analyses. The analytic results demonstrated that 2 upregulated DERNA (lncRNA U62317.3, KLHDC7B) and 1 downregulated DERNA (has-miR-375) may act as the key p16-positive-specific RNAs. There were 3 upregulated DERNA (lncRNA AL161431.1, hsa-miR-424-5p, PTHLH) and 2 downregulated DERNA (lncRNA ZNF667-AS1, FAM3B) may act as the key p16-negative-specific RNAs. Intriguingly, most of these
key RNAs have been well investigated in cancer. For example, downregulated IncRNA ZNF667-AS1 promoted the malignant progression and poor prognosis of cervical cancer, esophageal cancer, and laryngeal squamous cell carcinoma (LSCC)\textsuperscript{[30–32]}; miR-375 was downregulated in LSCC and decreased miR-375 indicated a poor outcome\textsuperscript{[33]}; miR-424-5p enhanced the aggressive progression of LSCC\textsuperscript{[34]}; KLHDC7B participated the breast cancer cell proliferation\textsuperscript{[35]}; PTHLH was a poor prognostic marker of HNSCC\textsuperscript{[36]}. These publications partially support the accuracy of our informatics analyses.
LncRNAs and miRNAs are involved in the regulation of gene expression via the ceRNA mechanism as previously described. By constructing the ceRNA network, our research focused on the potentially different regulatory mechanisms of p16-positive and p16-negative HNSCCs. Several previous studies have already reported the RNAs and the interactions between RNAs in the 2 ceRNA networks. For example, SNHG1, an upregulated IncRNA in the p16-positive ceRNA network, was reported to regulate colorectal cancer cell growth through interactions with miR-154-5p and EZH2.[37] SNHG1 was also reported to regulate NOB1 expression by sponging miR-326 and promotes tumorigenesis in osteosarcoma.[38] These previous studies strongly demonstrated that the regulatory relationship in our ceRNA network was reliable. SNHG12 was another upregulated IncRNA in the p16-positive ceRNA network and was reported to promote the progression of clear cell renal cell carcinoma, hepatocellular carcinoma, and osteosarcoma by sponging miRNAs.[39–41] KCNQ1OT1 was an upregulated IncRNA in the p16-negative ceRNA network and was reported to act as the ceRNA to promote the progression of colorectal cancer and bladder cancer.[42,43] In tongue cancer, it was reported that KCNQ1OT1 not only promoted proliferation but also induced cisplatin resistance.[44] One of the reasons that the prognosis of p16-negative HNSCC patients is significantly worse than p16-positive patients was regarded as chemotherapy resistance.[45] Based on the analyses of our study, KCNQ1OT1 and the ceRNA network in the p16-negative HNSCC were the potential biomarkers and treatment targets of chemoresistance. Several reports suggested that H19, a downregulated lncRNA in the p16-negative ceRNA network, is linked to the poor prognosis of cancer patients. H19 was reported to interact with miR-138-5p and therefore promote tumor proliferation in cervical cancer. H19 could also regulate keratinocyte differentiation by targeting miR-130-3p.[46] Furthermore, H19 expression was reported strongly correlated with miR-675-5p in colorectal cancer. The binding between miR-675-5p and the 3’UTR in the TP53 mRNA resulted in the loss of the p53 protein and metastasis.[47] Another downregulated IncRNA in the p16-positive ceRNA network, LINC00662, was reported to promote hepatocellular carcinoma progression via competitively binding miR-15a and miR-16.[48] According to our study, the downregulation of H19 and LINC00662 in the p16-positive group and the corresponding ceRNA networks might be the potential reason why the p16-positive group HNSCC patients usually have a better prognosis than the patients in the p16-negative group. In the p16-positive ceRNA network, 3 key mRNAs (PDLIM5, USP25, SLMAP) were confirmed to be correlated with OS. PDLIM5 has been reported to be a potential biomarker of papillary thyroid carcinoma[49]; USP25 cancer-associated mutations led to activation in vitro and in vivo[50]; SLMAP was a target gene of miR-224 and regulated giant tumor-derived neoplastic stromal cells.[51] In the p16-negative group ceRNA network, 2 key mRNAs (ITGA5, ADA) were identified to be associated with OS. ITGA5 was reported to correlate with poor OS in colorectal adenocarcinoma,[52] pancreatic cancer, and inhibited the efficacy of chemotherapy in pancreatic cancer.[53] ADA exosomes in HNSCC plasma was regarded as a potential marker of tumor progression and immune competence.[54] These reports further imply the accuracy of our current analytic results. However, more researches and large-scale clinical trials are needed to explore the molecular mechanisms and the prognostic value of these key RNAs in p16-positive and p16-negative HNSCC.

5. Conclusions

In conclusion, HNSCC patients with p16-positive and p16-negative status have differential RNA expression profiling and differential ceRNA network. The findings of our analyses introduce new insights into HPV-related HNSCC and suggest that the key RNAs in the p16-positive and p16-negative group may be potential biomarkers and therapeutic targets for different p16-status patients. Further studies with multicenter data, larger clinical samples, and more lab experiments are needed to verify these findings.

Acknowledgments

The authors are thankful to the TCGA database (https://cancer.gov/).

Author contributions

Conceptualization: Yifan Yang. Data curation: Ling Feng, Ru Wang. Methodology, Software: Yifan Yang, Ling Feng. Project administration and Supervision: Jugao Fang. Validation: Hongzhi Ma, Shizhi He. Writing—original draft: Yifan Yang. Writing—review and editing: Yifan Yang, Ling Feng, Ru Wang, Jugao Fang.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
[2] Hashim D, Genden E, Posner M, et al. Head and neck cancer prevention: from primary prevention to impact of clinicians on reducing burden. Ann Oncol. 2019;30:744–5.
[3] Castellsague X, Alemany L, Quer M, et al. HPV Involvement in head and neck cancers: comprehensive assessment of biomarkers in 3680 patients. J Natl Canc Inst. 2016;108:dyv403.
[4] Chaturvedi AV, Engels EA, Anderson WF, et al. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612–9.
[5] Rietbergen MM, Braakenhoff RH, Bloemena E, et al. Human papillomavirus detection and comorbidity: critical issues in selection of patients with oropharyngeal cancer for treatment de-escalation trials. Ann Oncol. 2015;26:2740–5.
[6] Li H, Torabi SJ, Yarbrough WG, et al. Association of human papillomavirus status at head and neck carcinoma subsites with overall survival. JAMA Otolaryngol Head Neck Surg. 2018;144:519–25.
[7] Wasylyk B, Abecassiss J, Jung AC. Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncol. 2013;49:e33–7.
[8] Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options Oncol. 2017;18:40.
[9] Fakhry C, Llacquet C, Rooper LM, et al. Human papillomavirus testing in head and neck carcinomas: ASCO clinical practice guideline endorsement of the college of american pathologists guideline. J Clin Oncol. 2018;36:3152–61.
[10] ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012;489:57–74.
[11] Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172:393–407.
[12] Ferro E, Enrico Bena C, Grigolon S, et al. From endogenous to synthetic microRNA-mediated regulatory circuits: an overview. Cells. 2019;8:1540.
[13] Salmona L, Poliseno L, Tay Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146:533–8.
[14] Dong Z, Zhang A, Liu S, et al. Aberrant methylation-mediated silencing of IncRNA MEG3 functions as a ceRNA in esophageal cancer. Mol Cancer Res. 2017;15:800–10.
[15] Cao Q, Dong Z, Liu S, et al. Construction of a metastasis-associated ceRNA network reveals a prognostic signature in lung cancer. Cancer Cell Int. 2020;20:208.
[16] Chen C, Jiang L, Zhang Y, et al. FOXA1-induced LINC01207 facilitated neck squamous cell carcinoma via up-regulation of TNRc6B. Biomed Pharmacother. 2020;128:110220.
[17] Li R, Qiu H, Wang S, et al. GDCRNAtools: an R/Bioconductor package for integrative analysis of IncRNA, miRNA and mRNA data in GDC. Bioinformatics. 2018;34:255–7.
[18] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
[36] Chang WM, Lin YF, Su CY, et al. Parathyroid hormone-like hormone
[35] Jeong G, Bae H, Jeong D, et al. A Kelch domain-containing KLHDC7B
[34] Li Y, Liu J, Hu W, et al. miR-424-5p promotes proliferation, migration
[32] Meng W, Cui W, Zhao L, et al. Aberrant methylation and downregu-
[30] Zhao LP, Li RH, Han DM, et al. Independent prognostic factor of
[29] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the
[28] D’Souza G, Anantharaman D, Gheit T, et al. Effect of HPV on head and
[26] Zhu Y, Xia X, Gross N, et al. Prognostic implications of human papil-
[24] Martinez-Zapien D, Ruiz F, Poirson J, et al. Structure of the E6/E6AP/
[22] Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res.
[21] Dimova DK, Dyson NJ. The E2F transcriptional network: old acquain-
[20] Maxwell JH, Grandis JR, Ferris RL. HPV-associated head and neck
[19] Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival
[18] of 1362 cases across three continents. Oral Oncol. 2016;62:20–7.
[17] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the
[16] Sauer F, Klemm T, Kollampally RB, et al. Differential oligomerization
[15] Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes
[14] Cen B, Lang JD, Du Y, et al. Prostaglandin E(2) induces miR675-5p to
[13] Hu A, Huang JJ, Xu WH, et al. Mir-21/mir-375 ratio is an independ-
[12] Meng W, Cui W, Zhao L, et al. Aberrant methylation and downregula-
[11] Zhou S, Yu L, Xiong M, et al. LncRNA SNHG12 promotes tumorigen-
[10] Lan T, Ma W, Hong Z, et al. Long non-coding RNA small nuclearal
host gene 12 (SNHG12) promotes tumorigenesis and metastasis by
[9] Sauer F, Klemm T, Kollampally RB, et al. Differential oligomerization
[8] of head squamous cell carcinoma. Cancer Lett. 2018;391:1–9.
[7] Xu M, Chen X, Lin K, et al. The long noncoding RNA SNHG1 regu-
lates colorectal cancer cell growth through interactions with EZH2 and
[6] Wang J, Cao L, Wu J, et al. Long non-coding RNA SNHG1 regulates
[5] Wang J, Zhang H, Situ J, et al. KCNQ1OT1 aggravates cell prolifera-
[4] Zhang S, Ma H, Zhang D, et al. LncRNA KCNQ1OT1 regulates prolif-
[3] Reid P, Marcu LG, Olver I, et al. Diversity of cancer stem cells in head
[2] Li CX, Li HG, Huang LT, et al. H19 IncRNA regulates keratinocyte dif-
finition. Mol Oncol. 2020;14:462–83.
[1] Wei X, Zhang, Yuan Y, et al. PDILIM5 identified by label-free quanti-
tative proteomics as a potential novel biomarker of papillary thyroid
carcinoma. Biochem Biophys Res Commun. 2018;499:338–44.
[10] Tian X, Wu Y, Yang Y, et al. Long noncoding RNA LINC00662 promotes
[9] Cen B, Lang JD, Du Y, et al. Prostaglandin E(2) induces miR675-5p to
[8] of the deubiquitinases USP25 and USP28 regulates their activities. Mol
[7] Zhao et al. • Medicine (2022) 101:33 www.md-journal.com

[19] Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival
of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
[20] Maxwell JH, Grands JR, Ferris RL. HPV-associated head and neck
cancer: unique features of epidemiology and clinical management.
Annu Rev Med. 2016;67:91–101.
[21] Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaint-
tances with new faces. Oncogene. 2005;24:2810–26.
[22] Serrano M. The tumor suppressor protein p16INK4a. Exp Cell Res.
1997;237:7–13.
[23] Scheffner M, Werness B, Huibregtse J, et al. The E6 oncoprotein
encoded by human papillomavirus types 16 and 18 promotes the degrada-
tion of p53. Cell. 1990;63:1129–36.
[24] Martinez-Zapien D, Ruiz F, Poisson J, et al. Structure of the E6/E6AP/
p53 complex required for HPV-mediated degradation of p53. Nature.
2016;529:541–5.
[25] Lydiah WM, Patel SG, O’Sullivan B, et al. Head and neck cancers-ma-
jor changes in the American Joint Committee on cancer eighth edition
cancer staging manual. CA Cancer J Clin. 2017;67:122–37.
[26] Zhu Y, Xia X, Gross N, et al. Prognostic implications of human papil-
mavirus status and p16 expression in laryngeal squamous cell carcino-
ma. Head Neck. 2019;41:4151–63.
[27] Ko HC, Harari PM, Sacotte RM, et al. Prognostic implications of
human papillomavirus status for patients with non-oropharyngeal
head and neck squamous cell carcinomas. J Cancer Res Clin Oncol.
2017;143:2341–50.
[28] D’Souza G, Anantharaman D, Gheit T, et al. Effect of HPV on head and
neck cancer patient survival, by region and tumor site: a comparison of
1362 cases across three continents. Oral Oncol. 2016;62:20–7.
[29] Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the
unification of biology. The Gene Ontology Consortium. Nat Genet.
2000;25:25–9.
[30] Zhao LP, Li RH, Han DM, et al. Independent prognostic factor of
low-expressed LncRNA ZNF667-AS1 for cervical cancer and inhibi-
tory function on the proliferation of cervical cancer. Eur Rev Med
Pharmacol Sci. 2017;21:5353–60.
[31] Dong Z, Li S, Wu X, et al. Ablative hypermethylation-mediated
downregulation of antisense IncRNA ZNF667-AS1 and its sense gene
ZNF667 correlate with progression and prognosis of esophageal squa-
mo-cell carcinoma. Cell Death Dis. 2019;10:930.
[32] Meng W, Cui W, Zhao L, et al. Aberrant methylation and downregula-
tion of ZNF667-AS1 and ZNF667 promote the malignant progression
of laryngeal squamous cell carcinoma. J Biomed Sci. 2019;26:13.
[33] Hu A, Huang JJ, Xu WH, et al. MiR-21/mir-375 ratio is an indepen-
dent prognostic factor in patients with laryngeal squamous cell carci-
noma. Am J Cancer Res. 2015;5:1775–85.
[34] Li Y, Liu J, Hu W, et al. mir-424-5p promotes proliferation, migration
and invasion of laryngeal squamous cell carcinoma. Onco Targets Ther.
2019;12:10441–53.
[35] Jeong G, Bae H, Jeong D, et al. A Kelch domain-containing KLHDC7B
and a long non-coding RNA ST8SIA6-AS1 act oppositely on breast
breast cancer proliferation via the interferon signaling pathway. Sci Rep.
2018;8:12922.
[36] Chang WM, Lin YF, Su CY, et al. Parathyroid hormone-like hormone is
a poor prognosis marker of head and neck cancer and promotes cell
growth via RUNX2 regulation. Sci Rep. 2017;7:41131.